Top

Journal of NeuroEngineering and Rehabilitation

Published in:

Open Access 01-12-2005 | Research

Gait dynamics in mouse models of Parkinson's disease and Huntington's disease

Authors: Ivo Amende, Ajit Kale, Scott McCue, Scott Glazier, James P Morgan, Thomas G Hampton

Published in: Journal of NeuroEngineering and Rehabilitation | Issue 1/2005

Abstract

Background

Gait is impaired in patients with Parkinson's disease (PD) and Huntington's disease (HD), but gait dynamics in mouse models of PD and HD have not been described. Here we quantified temporal and spatial indices of gait dynamics in a mouse model of PD and a mouse model of HD.

Methods

Gait indices were obtained in C57BL/6J mice treated with the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 30 mg/kg/day for 3 days) for PD, the mitochondrial toxin 3-nitropropionic acid (3NP, 75 mg/kg cumulative dose) for HD, or saline. We applied ventral plane videography to generate digital paw prints from which indices of gait and gait variability were determined. Mice walked on a transparent treadmill belt at a speed of 34 cm/s after treatments.

Results

Stride length was significantly shorter in MPTP-treated mice (6.6 ± 0.1 cm vs. 7.1 ± 0.1 cm, P < 0.05) and stride frequency was significantly increased (5.4 ± 0.1 Hz vs. 5.0 ± 0.1 Hz, P < 0.05) after 3 administrations of MPTP, compared to saline-treated mice. The inability of some mice treated with 3NP to exhibit coordinated gait was due to hind limb failure while forelimb gait dynamics remained intact. Stride-to-stride variability was significantly increased in MPTP-treated and 3NP-treated mice compared to saline-treated mice. To determine if gait disturbances due to MPTP and 3NP, drugs affecting the basal ganglia, were comparable to gait disturbances associated with motor neuron diseases, we also studied gait dynamics in a mouse model of amyotrophic lateral sclerosis (ALS). Gait variability was not increased in the SOD1 G93A transgenic model of ALS compared to wild-type control mice.

Conclusion

The distinct characteristics of gait and gait variability in the MPTP model of Parkinson's disease and the 3NP model of Huntington's disease may reflect impairment of specific neural pathways involved.

Available only for authorised users

Salarian A, Russmann H, Vingerhoets FJ, Dehollain C, Blanc Y, Burkhard PR, Aminian K: Gait assessment in Parkinson's disease: toward an ambulatory system for long-term monitoring. IEEE Trans Biomed Eng 2004, 51: 156-159. 10.1109/TBME.2004.827933CrossRef

Weller C, O'Neill CJ, Charlett A, Bowes SG, Purkiss A, Nicholson PW, Dobbs RJ, Dobbs SM: Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor. Br J Clin Pharmacol 1993, 35: 379-385.PubMedCentralCrossRefPubMed

Bartolic A, Pirtosek Z, Rozman J, Ribaric S: Postural stability of Parkinson's disease patients is improved by decreasing rigidity. Eur J Neurol 2005, 12: 156-159. 10.1111/j.1468-1331.2004.00942.xCrossRefPubMed

Nieuwboer A, Dom R, De Weerdt W, Desloovere K, Fieuws S, Broens-Kaucsik E: Abnormalities of the spatiotemporal characteristics of gait at the onset of freezing in Parkinson's disease. Mov Disord 2001, 16: 1066-1075. 10.1002/mds.1206CrossRefPubMed

Thaut MH, Miltner R, Lange HW, Hurt CP, Hoemberg V: Velocity modulation and rhythmic synchronization of gait in Huntington's disease. Mov Disord 1999, 14: 808-819. PublisherFullText 10.1002/1531-8257(199909)14:5<808::AID-MDS1014>3.0.CO;2-JCrossRefPubMed

Koller WC, Trimble J: The gait abnormality of Huntington's disease. Neurology 1985, 35: 1450-1454.CrossRefPubMed

Bilney B, Morris ME, Churchyard A, Chiu E, Georgiou-Karistianis N: Evidence for a disorder of locomotor timing in Huntington's disease. Mov Disord 2005, 20: 51-57. 10.1002/mds.20294CrossRefPubMed

Tian J, Herdman SJ, Zee DS, Folstein SE: Postural stability in patients with Huntington's disease. Neurology 1992, 42: 1232-1238.CrossRefPubMed

Hausdorff JM, Cudkowicz ME, Firtion R, Wei JY, Goldberger AL: Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease. Mov Disord 1998, 13: 428-437. 10.1002/mds.870130310CrossRefPubMed

10.

Blin O, Ferrandez AM, Serratrice G: Quantitative analysis of gait in Parkinson patients: increased variability of stride length. J Neurol Sci 1990, 98: 91-97. 10.1016/0022-510X(90)90184-OCrossRefPubMed

11.

Schaafsma JD, Giladi N, Balash Y, Bartels AL, Gurevich T, Hausdorff JM: Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa. J Neurol Sci 2003, 212: 47-53. 10.1016/S0022-510X(03)00104-7CrossRefPubMed

12.

Djaldetti R, Melamed E: New drugs in the future treatment of Parkinson's disease. J Neurol 2002,249(Suppl 2):II30-35.PubMed

13.

Bonelli RM, Wenning GK, Kapfhammer HP: Huntington's disease: present treatments and future therapeutic modalities. Int Clin Psychopharmacol 2004, 19: 51-62. 10.1097/00004850-200403000-00001CrossRefPubMed

14.

Fernagut PO, Diguet E, Labattu B, Tison F: A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Methods 2002, 113: 123-130. 10.1016/S0165-0270(01)00485-XCrossRefPubMed

15.

Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ: Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 1999, 19: 3248-3257.PubMed

16.

Kopin IJ: MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease. Environ Health Perspect 1987, 75: 45-51. 10.2307/3430575PubMedCentralCrossRefPubMed

17.

Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK: MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 2000, 30: 171-182. 10.1023/A:1001958023096CrossRefPubMed

18.

Jakowec MW, Petzinger : GM.1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates. Comp Med 2004, 54: 497-513.PubMed

19.

Gupta M, Felten DL, Gash DM: MPTP alters central catecholamine neurons in addition to the nigrostriatal system. Brain Res Bull 1984, 13: 737-742. 10.1016/0361-9230(84)90234-XCrossRefPubMed

20.

Sedelis M, Schwarting RK, Huston JP: Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001, 125: 109-125. 10.1016/S0166-4328(01)00309-6CrossRefPubMed

21.

Schulz JB, Matthews RT, Klockgether T, Dichgans J, Beal MF: The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol Cell Biochem 1997, 174: 193-197. 10.1023/A:1006852306789CrossRefPubMed

22.

Santamaria A, Perez-Severiano F, Rodriguez-Martinez E, Maldonado PD, Pedraza-Chaverri J, Rios C, Segovia J: Comparative analysis of superoxide dismutase activity between acute pharmacological models and a transgenic mouse model of Huntington's disease. Neurochem Res 2001, 26: 419-424. 10.1023/A:1010911417383CrossRefPubMed

23.

Guyot MC, Hantraye P, Dolan R, Palfi S, Maziere M, Brouillet E: Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience 1997, 7: 45-56. 10.1016/S0306-4522(96)00602-1CrossRef

24.

Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF: Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A 1995, 92: 7105-7109. 10.1073/pnas.92.15.7105PubMedCentralCrossRefPubMed

25.

Diguet E, Fernagut PO, Wei X, Du Y, Rouland R, Gross C, Bezard E, Tison F: Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci 2004, 19: 3266-3276. 10.1111/j.0953-816X.2004.03372.xCrossRefPubMed

26.

Dunham NW, Miya TS: A note on a simple apparatus for detecting neurological deficit in rat and mice. J Am Pharm Ass 1957, 46: 208-209.CrossRefPubMed

27.

Rozas G, Lopez-Martin E, Guerra MJ, Labandeira-Garcia JL: The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 1998, 83: 165-175. 10.1016/S0165-0270(98)00078-8CrossRefPubMed

28.

Willis GL, Donnan GA: Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res 1987, 402: 269-274. 10.1016/0006-8993(87)90033-3CrossRefPubMed

29.

Fernagut PO, Diguet E, Stefanova N, Biran M, Wenning GK, Canioni P, Bioulac B, Tison F: Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Neuroscience 2002, 114: 1005-1017.CrossRefPubMed

30.

Fernagut PO, Diguet E, Jaber M, Bioulac B, Tison F: Dopamine transporter knock-out mice are hypersensitive to 3-nitropropionic acid-induced striatal damage. Eur J Neurosci 2002, 15: 2053-2056. 10.1046/j.1460-9568.2002.02047.xCrossRefPubMed

31.

Weihmuller FB, Hadjiconstantinou M, Bruno JP: Acute stress or neuroleptics elicit sensorimotor deficits in MPTP-treated mice. Neurosci Lett 1988, 85: 137-42. 10.1016/0304-3940(88)90443-0CrossRefPubMed

32.

Ryu JK, Kim J, Cho SJ, Hatori K, Nagai A, Choi HB, Lee MC, McLarnon JG, Kim SU: Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease. Neurobiol Dis 2004, 16: 68-77. 10.1016/j.nbd.2004.01.016CrossRefPubMed

33.

Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y: A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 1988, 50: 435-441.

34.

Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, Sudhof TC: Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A 2005, 2: 3413-3418. 10.1073/pnas.0409713102CrossRef

35.

Vieregge P, Stolze H, Klein C, Heberlein I: Gait quantitation in Parkinson's disease – locomotor disability and correlation to clinical rating scales. J Neural Transm 1997, 104: 237-248. 10.1007/BF01273184CrossRefPubMed

36.

Hausdorff JM, Lertratanakul A, Cudkowicz ME, Peterson AL, Kaliton D, Goldberger AL: Dynamic markers of altered gait rhythm in amyotrophic lateral sclerosis. J Appl Physiol 2000, 88: 2045-2053.PubMed

37.

Kale A, Amende I, Meyer GP, Crabbe JC, Hampton TG: Ethanol's effects on gait dynamics in mice investigated by ventral plane videography. Alcohol Clin Exp Res 2004, 28: 1839-1848. 10.1097/01.ALC.0000148103.09378.81CrossRefPubMed

38.

Hampton TG, Stasko MR, Kale A, Amende I, Costa AC: Gait dynamics in trisomic mice: quantitative neurological traits of Down syndrome. Physiol Behav 2004, 82: 381-389. 10.1016/j.physbeh.2004.04.006CrossRefPubMed

39.

Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Chen W, Zhai P, Sufit RL, Siddique T: Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264: 1772-1775. 10.1126/science.8209258CrossRefPubMed

40.

Colotla VA, Flores E, Oscos A, Meneses A, Tapia R: Effects of MPTP on locomotor activity in mice. Neurotoxicol Teratol 1990, 12: 405-407. 10.1016/0892-0362(90)90061-GCrossRefPubMed

41.

Shimoji M, Zhang L, Mandir AS, Dawson VL, Dawson TM: Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease. Brain Res Mol Brain Res 2005, 134: 103-108. 10.1016/j.molbrainres.2005.01.012CrossRefPubMed

42.

Gabrielson KL, Hogue BA, Bohr VA, Cardounel AJ, Nakajima W, Kofler J, Zweier JL, Rodriguez ER, Martin LJ, de Souza-Pinto NC, Bressler J: Mitochondrial toxin 3-nitropropionic acid induces cardiac and neurotoxicity differentially in mice. Am J Pathol 2001, 159: 1507-1520.PubMedCentralCrossRefPubMed

43.

Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, Glass JD: Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 2004, 185: 232-240. 10.1016/j.expneurol.2003.10.004CrossRefPubMed

44.

Puttaparthi K, Gitomer WL, Krishnan U, Son M, Rajendran B, Elliott JL: Disease progression in a transgenic model of familial amyotrophic lateral sclerosis is dependent on both neuronal and non-neuronal zinc binding proteins. J Neurosci 2002, 22: 8790-8796.PubMed

45.

Barneoud P, Lolivier J, Sanger DJ, Scatton B, Moser P: Quantitative motor assessment in FALS mice: a longitudinal study. Neuroreport 1997, 8: 2861-2865.CrossRefPubMed

46.

Hamers FP, Lankhorst AJ, van Laar TJ, Veldhuis WB, Gispen WH: Automated quantitative gait analysis during overground locomotion in the rat: Its application to spinal cord contusion and transection injuries. J Neurotrauma 2001, 18: 187-201. 10.1089/08977150150502613CrossRefPubMed

47.

Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF: Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 2004, 24: 9434-9440. 10.1523/JNEUROSCI.3080-04.2004CrossRefPubMed

48.

Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ: Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 2001, 10: 137-144. 10.1093/hmg/10.2.137CrossRefPubMed

49.

50.

Naver B, Stub C, Moller M, Fenger K, Hansen AK, Hasholt L, Sorensen SA: Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 2003, 122: 1049-1057. 10.1016/j.neuroscience.2003.08.053CrossRefPubMed

51.

Muralikrishnan D, Mohanakumar KP: Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998, 12: 905-912.PubMed

52.

Rousselet E, Joubert C, Callebert J, Parain K, Tremblay L, Orieux G, Launay JM, Cohen-Salmon C, Hirsch EC: Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiol Dis 2003, 14: 218-228. 10.1016/S0969-9961(03)00108-6CrossRefPubMed

53.

Tsai YF, Tsai HW, Tai MY, Lu KS: Age-related changes in locomotor behavior induced by MPTP in rats. Neurosci Lett 1991, 129: 153-155. 10.1016/0304-3940(91)90743-DCrossRefPubMed

54.

Clarke KA, Still J: Gait analysis in the mouse. Physiol Behav 1999, 66: 723-729. 10.1016/S0031-9384(98)00343-6CrossRefPubMed

55.

Prochazka A, Gillard D, Bennett DJ: Positive force feedback control of muscles. J Neurophysiol 1997, 77: 3226-3236.PubMed

56.

Koutouzis TK, Borlongan CV, Scorcia T, Creese I, Cahill DW, Freeman TB, Sanberg PR: Systemic 3-nitropropionic acid: long-term effects on locomotor behavior. Brain Res 1994, 646: 242-246. 10.1016/0006-8993(94)90085-XCrossRefPubMed

57.

Cools AR, Jongen-Relo AL: Role of neostriatum and nucleus accumbens in stepping induced by apomorphine and dexamphetamine. Brain Res Bull 1991, 26: 909-917. 10.1016/0361-9230(91)90256-JCrossRefPubMed

58.

Shimano Y, Kumazaki M, Sakurai T, Hida H, Fujimoto I, Fukuda A, Nishino H: Chronically administered 3-nitropropionic acid produces selective lesions in the striatum and reduces muscle tonus. Obes Res 1995,3(Suppl 5):779S-784S.CrossRefPubMed

59.

Abernethy B, Hanna A, Plooy A: The attentional demands of preferred and non-preferred gait patterns. Gait Posture 2002, 15: 256-265. 10.1016/S0966-6362(01)00195-3CrossRefPubMed

60.

Shear DA, Haik KL, Dunbar GL: Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats. Neuroreport 2000, 11: 1833-1837. 10.1097/00001756-200006260-00007CrossRefPubMed

61.

Smith MA, Brandt J, Shadmehr R: Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature 2000, 403: 544-549. 10.1038/35000576PubMedCentralCrossRefPubMed

62.

Wooley CM, Sher RB, Kale A, Frankel WN, Cox GA, Seburn KL: Gait analysis detects early changes in transgenic SOD1(G93A) mice. Muscle Nerve 2005, 32: 43-50. 10.1002/mus.20228PubMedCentralCrossRefPubMed

63.

Kuo JJ, Schonewille M, Siddique T, Schults AN, Fu R, Bar PR, Anelli R, Heckman CJ, Kroese AB: Hyperexcitability of cultured spinal motoneurons from presymptomatic ALS mice. J Neurophysiol 2004, 91: 571-575. 10.1152/jn.00665.2003CrossRefPubMed

64.

Dengler R, Konstanzer A, Kuther G, Hesse S, Wolf W, Struppler A: Amyotrophic lateral sclerosis: macro-EMG and twitch forces of single motor units. Muscle Nerve 1990, 13: 545-550. 10.1002/mus.880130612CrossRefPubMed

65.

Brach JS, Berlin JE, VanSwearingen JM, Newman AB, Studenski SA: Too much or too little step width variability is associated with a fall history in older persons who walk at or near normal gait speed. Journal of NeuroEngineering and Rehabilitation 2005, in press.

66.

Menz HB, Latt MD, Tiedemann A, Mun San Kwan M, Lord SR: Reliability of the GAITRite walkway system for the quantification of temporo-spatial parameters of gait in young and older people. Gait Posture 2004, 20: 20-25. 10.1016/S0966-6362(03)00068-7CrossRefPubMed

67.

Gabell A, Nayak US: The effect of age on variability in gait. J Gerontol 1984, 39: 662-666.CrossRefPubMed

68.

Budsberg SC, Verstraete MC, Soutas-Little RW: Force plate analysis of the walking gait in healthy dogs. Am J Vet Res 1987, 48: 915-918.PubMed

69.

Cohen AH, Gans C: Muscle activity in rat locomotion: movement analysis and electromyography of the flexors and extensors of the elbow. J Morphol 1975, 146: 177-196. 10.1002/jmor.1051460202CrossRefPubMed

70.

Bezard E, Dovero S, Bioulac B, Gross C: Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp Neurol 1997, 148: 288-292. 10.1006/exnr.1997.6648CrossRefPubMed

71.

Brownell AL, Chen YI, Yu M, Wang X, Dedeoglu A, Cicchetti F, Jenkins BG, Beal MF: 3-Nitropropionic acid-induced neurotoxicity – assessed by ultra high resolution positron emission tomography with comparison to magnetic resonance spectroscopy. J Neurochem 2004, 89: 1206-1214. 10.1111/j.1471-4159.2004.02408.xCrossRefPubMed

72.

Gupta M, Gupta BK, Thomas R, Bruemmer V, Sladek JR Jr, Felten DL: Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults. Neurosci Lett 1986, 70: 326-331. 10.1016/0304-3940(86)90573-2CrossRefPubMed

73.

Brouillet E, Jenkins BG, Hyman BT, Ferrante RJ, Kowall NW, Srivastava R, Roy DS, Rosen BR, Beal M: Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 1993, 60: 356-359. 10.1111/j.1471-4159.1993.tb05859.xCrossRefPubMed

74.

Fuller RW, Hahn RA, Snoddy HD, Wikel JH: Depletion of cardiac norepinephrine in rats and mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Pharmacol 1984, 33: 2957-2960. 10.1016/0006-2952(84)90593-8CrossRefPubMed

75.

Leblond H, L'Esperance M, Orsal D, Rossignol S: Treadmill locomotion in the intact and spinal mouse. J Neurosci 2003, 23: 11411-11419.PubMed

Title: Gait dynamics in mouse models of Parkinson's disease and Huntington's disease
Authors: Ivo Amende
Ajit Kale
Scott McCue
Scott Glazier
James P Morgan
Thomas G Hampton
Publication date: 01-12-2005
Publisher: BioMed Central
Published in: Journal of NeuroEngineering and Rehabilitation / Issue 1/2005
Electronic ISSN: 1743-0003
DOI: https://doi.org/10.1186/1743-0003-2-20

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Gait dynamics in mouse models of Parkinson's disease and Huntington's disease

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2005

Advances in wearable technology and applications in physical medicine and rehabilitation

How useful is satellite positioning system (GPS) to track gait parameters? A review

Wearable feedback systems for rehabilitation

Wearable kinesthetic system for capturing and classifying upper limb gesture in post-stroke rehabilitation

Obituary: Yukio Mano (1943–2004)

The development of postural strategies in children: a factorial design study